Emerging drugs and therapeutics for systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Fibrotic Diseases

Background:

• Systemic sclerosis (SSc) presents a significant therapeutic challenge due to its heterogeneous, multisystemic nature and complex pathophysiology.
• A lack of disease-modifying therapies necessitates organ-based management strategies for patient care, research, and drug development.
• Current research focuses on addressing life-threatening SSc manifestations like pulmonary arterial hypertension, interstitial lung disease, and vasculopathy.

Purpose of the Study:

• To review current and emerging treatment strategies for systemic sclerosis.
• To discuss the design and development of novel compounds targeting fibrotic processes in SSc.
• To highlight organ-based management approaches for severe SSc complications.

Main Methods:

• Review of existing literature on systemic sclerosis pathophysiology and treatment.
• Analysis of new therapeutic compounds and regimens targeting fibrotic disease processes.
• Discussion of organ-specific management strategies for SSc complications.

Main Results:

• Organ-based management strategies have improved outcomes for SSc, particularly for vascular complications.
• Development of novel compounds targeting SSc pathophysiology is ongoing but sparse.
• New treatment regimens involve both repurposed older drugs and newly discovered compounds.

Conclusions:

• Systemic sclerosis is a rare, heterogeneous disease with high morbidity and mortality.
• Organ-based strategies have enhanced SSc management, especially for vascular manifestations.
• Further research into SSc disease mechanisms is crucial for developing unifying treatment pathways.